Tilray Brands (TLRY) Asset Writedowns and Impairment (2017 - 2025)
Tilray Brands' (TLRY) quarterly Asset Writedowns and Impairment came in at $1.4 billion in Q2 2025, up 99.78% on a QoQ basis from $699.2 million in Q1 2025.
Tilray Brands (TLRY) Asset Writedowns and Impairment (2017 - 2025) Analysis & Trends
Tilray Brands (TLRY) has 8 years of Asset Writedowns and Impairment data on file, last reported at $1.4 billion in Q2 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $1.4 billion in Q2 2025, while the trailing twelve-month figure through May 2026 was $2.1 billion (changed 0.0% YoY) and the FY2025 annual result came in at $2.1 billion, changed N/A from the prior year.
- Asset Writedowns and Impairment improved to $1.4 billion in Q2 2025, from $699.2 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 billion in Q2 2025 to a low of $1000.0 in Q2 2023.
- A 4-year average of $569.4 million and a median of $532.7 million in 2022 frame the typical range for Asset Writedowns and Impairment.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment jumped 1738.65% — and 2023, when it slumped 100.0%.
- Tracing TLRY's Asset Writedowns and Impairment over 4 years: stood at $19.9 million in 2021, then jumped by 1738.65% to $366.2 million in 2022, then tumbled by 100.0% to $1000.0 in 2023, then surged by 139690300.0% to $1.4 billion in 2025.
- The last three Asset Writedowns and Impairment figures came in at $1.4 billion (Q2 2025), $699.2 million (Q1 2025), and $1000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Tilray Brands | 523.93 Mn | 289.30 Mn | 90.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | 1.40 Bn |
| May 31, 2025 | 1.40 Bn |
| Feb 28, 2025 | 699.24 Mn |
| Feb 28, 2025 | 699.24 Mn |
| May 31, 2023 | 1,000.00 |
| May 31, 2023 | 1,000.00 |
| Feb 28, 2023 | 934.00 Mn |
| Feb 28, 2023 | 934.00 Mn |
| May 31, 2022 | 366.24 Mn |
| May 31, 2022 | 366.24 Mn |
| May 31, 2021 | 19.92 Mn |
| May 31, 2021 | 19.92 Mn |
| May 31, 2020 | 50.16 Mn |
| May 31, 2020 | 50.16 Mn |
| Mar 31, 2020 | 29.84 Mn |
| Mar 31, 2020 | 29.84 Mn |
| Sep 30, 2019 | -275,000.00 |
| Sep 30, 2019 | -275,000.00 |
| May 31, 2019 | 56.92 Mn |
| May 31, 2019 | 56.92 Mn |